tbuckley/cabot-search huggingface dataset:
Identification of novel differentially methylated markers in adult acute lymphocytic leukemias
Authors: Shao-Qing Kuang, Hui Yang, Jaroslav Jelinek, Weigang Tong, Jean-Pierre Issa, Guillermo Garcia-Manero
Journal: Cancer Research (2007)

1131   Aberrant methylation of CpG islands (CGIs) in the promoter region of genes not only play roles in gene silencing, but is also potential biomarkers in diagnosis, prognosis study and in identification of novel cancer-related genes. In this study, we carried out a genome-wide search for aberrant CGIs methylation in adult acute lymphocytic leukemia (ALL) by using methylated CpG island amplification (MCA) / representational difference analysis (RDA). We identified 64 differentially methylated genes in ALL patients and 56 of them were novel mehylation targets. Methylation of 33 of these genes (Wnt2B, GIPC2, RSPO1, LHX4, TRIMP58, ECRG4, MAGI1, CAST1, ADCY5, HSPA4L, ZFP42, OCLN, EFNA5, MSX2, GFPT2, PNMA2, DPYSL2, GNA14, FOXE1, CRTAC1, DPYSL4, FANK, DHX32, DCAMKL1, AGC1, SALL1, SLC13A5, PTPRM, MYO5B, FOX027, ZNF382, MN1, PCDH11) were examined by pyrosequencing in 23 human leukemia cell lines and 10 normal peripheral lymphocytic cells (PBLCs). Except for TRIMP58, ECRG4, ZFP42, FANK , DHX32 and FOX027 which were hypermethylated in both leukemia cells lines and normal controls, the other genes were hypermethylated in at least 2 of the 23 leukemia cell lines but were not or only little methylated in normal PBLCs. In ALL patients, MAGI1, CAST1, ADCY5, HSPA4L, OCLN, EFNA5, GFPT2, GNA14, ZNF382 and MN1 genes were frequently hypermethylated (from 23 % to 87 %); GIPC2, RSPO1, MSX2, SALL1 and MYO5B were 100% methylated. Expression analysis of six selected genes (GIPC2, RSPO1, MAGI1, ADCY5, OCLN and GNA14) in leukemia cell lines by real-time PCR further confirmed methylation associated gene silencing and treatment of methylated/silenced cell lines with demethylating agent resulted in gene re-expression. Our results showed that MCA/RDA analysis allowed to global identification of aberrantly methylated CGIs in ALL and provide a panel of novel methylation biomarkers that could be useful in profiling for ALL and the other cancers.
Impaired hippocampal place cell dynamics in a mouse model of the 22q11.2 deletion
Authors: Jeffrey D Zaremba, Anastasia Diamantopoulou, Nathan B Danielson, Andres D Grosmark, Patrick W Kaifosh, John C Bowler, Zhenrui Liao, Fraser T Sparks, Joseph A Gogos, Attila Losonczy
Journal: Nature Neuroscience (2017)
THU0061 Regulation of osteoclast recruitment and activation by resolvin d1
Authors: HA Benabdoune, P Rondon, Q Shi, JC Fernandes, H Fahmi, M Benderdour
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Resolvin-D1 (RvD1) is a derivative of omega-3 fatty acids and a potent anti-inflammatory agent synthesized during the resolution phase of inflammation. In human cartilage, we recently reported that RvD1 strongly inhibited a number of factors involved in inflammation, catabolism, oxidative stress, and apoptosis. <h3>Objectives</h3> The overall objective of this study is to further investigate RvD1 effects on bone metabolism in vitro. <h3>Methods</h3> First, murine macrophages RAW267.4 were used to assess osteoclasts (OC) recruitment and bone resorption. RAW264.7 cells were incubated with 50 ng/ml LPS with or without RvD1 (0 - 10 μM) for 48 hours. Cell viability was verified with the MTS test. OC phenotype <i>markers, namely</i> TRAP and cathepsin-K, were assessed by western blot, enzymatic staining and immunocytochemistry. Levels of TNF-α, IL-1β, IL-6, IL-10, were measured by ELISA, and PGE<sub>2</sub> levels by EIA. NO release was measured by Greiss reaction. To investigate bone resorption, RAW264.7 cells were seeded in hydroxyapatite plates, then treated with 50 ng/ml LPS with or without RvD1 (0.5 and 1 μ M) for 48 hours. Plot formation was assessed by Von Kossa staining. Second, human osteoblasts (Ob) were obtained from post-surgery discarded trabecular bone of osteoarthritic (OA) patients who underwent total knee arthroplasty. First passage human OA Ob were treated either with RvD1 (0.1 - 1 μM) alone, or with 20 nM VitD3 with or without RvD1 (0.1 - 1 μ M), for 48 hours. Cell viability was evaluated with the MTS test. Alkaline phosphatase (PAL) activity and osteocalcin (OCN) release was determined by colorimetric reaction and ELISA, respectively. <h3>Results</h3> In RAW264.7 cells, our results clearly show that RvD1 strongly reduces OC recruitment and activation as indicated by the inhibition of TRAP and cathepsin K expression as well as TNF-α, IL-1β, IL-6, PGE<sub>2</sub> and NO release, as well as the concurrent enhancement of IL-10 levels. Besides, RvD1 decreases bone resorption through the inhibition of plots formation in hydroxyapatite matrix. In human OA Ob, RvD1 partially decreases VitD3-induced PAL activity, while it maintains OCN expression at control levels. <h3>Conclusions</h3> Our in vitro results clearly show that RvD1 may play an important role in the regulation of bone metabolism. Additionally to our previous data, our findings suggest that RvD1 may offer a novel and original perspective to make a real contribution to musculoskeletal and bone diseases therapy. <h3>Acknowledgements</h3> This study was supported by Canadian Institute of Health Research (CIHR) grant (#IMH 131570) and by the Center of Excellence for Arthroplasty Research. <h3>Disclosure of Interest</h3> None declared
若年(50歳以下)の心筋梗塞における臨床転帰の研究
Authors: Itoh Yoshiaki, Hirano Keisuke, Yamawaki Masahiro, Araki Motoharu, Kobayashi Norihiro, Takimura Hideyuki, Sakamoto Yasunari, Mouri Shinsuke, Tsutsumi Masakazu, Takama Takurou, Takafuji Hiroya, Maruyama Takashi, Honda Yohsuke, Tokuda Takahiro, Makino Kenji, Shirai Shigemitsu
Journal: Circulation (2016)
Herpesviruses as Oncogenic Agents
Authors: John E. Newbold, Ph.D.
Journal: JNCI Journal of the National Cancer Institute (1981)

Journal Article Herpesviruses as Oncogenic Agents Get access John E. Newbold, Ph.D. John E. Newbold, Ph.D. Departments of Bacteriology and Immunology The University of North Carolina at Chapel HillBox 30, Burnett Womack Clinical Science Building—229H Chapel Hill, North Carolina 27514 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 67, Issue 5, November 1981, Page 1176, https://doi.org/10.1093/jnci/67.5.1176 Published: 01 November 1981
免疫調節特性をもつフィブリノーゲン足場はin vivoで骨再生を促進する【Powered by NICT】
Authors: M Vasconcelos Daniel, M Goncalves Raquel, R Almeida Catarina, O Pereira Ines, I Oliveira Marta, Neves Nuno, M Silva Andreia, C Ribeiro Antonio, Cunha Carla, R Almeida Ana, C Ribeiro Cristina, M Gil Ana, Seebach Elisabeth, L Kynast Katharina, Richter Wiltrud, Lamghari Meriem, G Santos Susana, A Barbosa Mario
Journal: Biomaterials (2016)
Abstract 46: Study of Symptoms Variation in the Morning and Evening in Postural Orthostatic Tachycardia Syndrome (POTS)
Authors: Muhammad M Ahsan, Tara Thompson, Chandralekha Ashangari, Amer Suleman
Journal: Circulation Research (2016)

Background: Postural Orthostatic Tachycardia Syndrome (POTS) is a form of dysautonomia that is estimated to impact between 1,000,000 and 3,000,000 Americans and millions more around the world. Patients chronically have symptoms that are worse with upright posture and that improve with recumbence. Symptoms often include orthostatic intolerance such as dizziness, fatigue, excessive sweating and many others. The aim of this study is to determine the variation of symptoms early morning after wake up and evening at 4 PM. Methods: The Autonomic nervous system questionnaire consisting of eight POTS symptoms palpitations, headaches, dizziness, shortness of breath(SOB), chest pain, weakness, blurred vision and heaviness of feet was handover to the patients at our clinic. 42 POTS patients participated in the study, participated patients had been asked to scale their symptoms early morning after wake up and evening at 4 PM. Symptoms were defined 0 as Never,1 as mild,2 as moderate,3 as severe ,4 as extreme and 5 impairing daily function and living. Results: Out of 42 POTS patients 90% are female (38/42, age 31.74±10.67) and 10% are males (4/42, age 30.75±13.20), symptoms were scaled early morning after wake up vs symptoms scaled evening at 4 pm results in mean±SD and Anova P value. Palpitations 1.69±1.32 vs 2.45±1.38 (P =0.01), Dizziness 2.40±1.38 vs 2.67±1.46 (P =0.40), Chest pain 0.93±1.02 vs 1.52±1.27 (P=0.02), SOB 1.36±1.32 vs 1.81±1.40 (P=0.13), Weakness 2.79±1.37 vs 3.12±1.38 (P=0.27), Blurred vision 1.38±1.29 vs 1.48±1.27 (P=0.73), Headaches 1.74±1.36 vs 2.52±1.38 (P =0.01), Heaviness of feet 0.95±1.19 vs 1.43±1.53 (P =0.11). Conclusion: Our study results demonstrated that the patients with POTS had significant variation in symptoms Palpitations, Chest pain, Headaches in evenings when compared to early morning after wake up.
Chronic actinic dermatitis: successful treatment with psoralen-ultraviolet A photochemotherapy
Authors: S.N. Chee, L. Novakovic, H. Fassihi, T. Garibaldinos, R. Sarkany
Journal: British Journal of Dermatology (2017)

Chronic actinic dermatitis (CAD) is a debilitating photodermatosis. First line therapy consists of strict photoprotection and topical corticosteroids. Second line therapy uses systemic immunosuppression. However an alternative is needed for patients with severe CAD who cannot use systemic immunosuppressants.1,2 Case reports and small case series suggest that PUVA may be effective.3-6

This article is protected by copyright. All rights reserved.+
Involvement of oligosaccharide changes in alpha5beta1 integrin in a cisplatin-resistant human squamous cell carcinoma cell line
Authors: Hong Jiang, Candelaria Gomez-Manzano, Diana Medrano, Andrea Cass, Marta M. Alonso, Ramon Alemany, Alfred Yung, Juan Fueyo
Journal: Cancer Research (2004)

1203   Multiple mechanisms are involved in the resistance of cancer cells to cisplatin including, the expression of multidrug resistance-associated protein (MRP) and enhanced DNA repair. Here, we report findings to show that oligosaccharide changes in alpha5beta1 integrin are associated with cisplatin resistance in a head and neck squamous cell carcinoma cell line, HSC-2. Cisplatin-resistant HSC-2 (HSC-2/CR) cells were established by step-wise treatment with various concentrations of cisplatin. The oligosaccharides containing beta1-6GlcNAc branching, detected by L4-PHA lectin blot, were found to be dramatically decreased in alpha5beta1 integrin immunoprecipitated from HSC-2/CR cells. To better understand the mechanisms underlying cisplatin resistance and oligosaccharide alteration, we analyzed the down-stream signaling of alpha5beta1 integrin, one of the target glycoproteins of beta1-6GlcNAc transferase (GnT-V). Cell adhesion to fibronectin, as well as phosphorylation of focal adhesion kinase (FAK), these molecules associated with alpha5beta1 integrin and involved in a cell survival signaling were found to be increased in the cisplatin-resistant cells. Enhancement of the inhibition of cell adhesion and FAK phosphorylation also support the above data in GnT-V-overexpressed transfectants. Interestingly, the differences in sensitivity to cisplatin and FAK phosphorylation between cisplatin-sensitive and –resistant cells were completely abolished by treatment with a neutral antibody of alpha5beta1 integrin. These results suggest that modification of oligosaccharides of alpha5beta1 integrin represents one of the possible mechanisms of drug-resistance in head and neck cancer cells. Fig. GnT-V transfected HSC-2 cells showed decreases in cisplatin resistance.
Abstract #1822: Mechanistic studies of a novel small molecule anticancer drug, LOR-253, on cell cycle arrest and angiogenesis
Authors: Mario Huesca, Mei Wang, Howard Cukier, Venkata Nedunuri, Hongnan Jin, Robert Peralta, Yoon Lee, Aiping Young
Journal: Cancer Research (2009)

LOR-253 is an anticancer drug candidate in late stage preclinical development that is advancing to clinical studies based on the results of recently completed IND-enabling GLP toxicology studies. Previously we reported that chelation of intracellular labile zinc by LOR-253 results in Kruppel like factor 4 (KLF4) induction leading to cyclin D1 repression and cell cycle arrest in HT-29 colon carcinoma cells. Cyclin D1 is a downstream target of \#946;-catenin, whose transcription is regulated by KLF4; therefore we investigated the involvement of the Wnt/\#946;-catenin signaling pathway in the mode of action of LOR-253. \#914;-catenin gene expression was analyzed by RT-PCR in samples extracted from HT-29 colon cancer cells treated with LOR-253 in vitro, and from HT-29 xenograft tumors from treated CD-1 nude mice. These studies demonstrated that LOR-253 mediated induction of KLF4 led to a decrease in \#946;-catenin expression, resulting in reduction of cyclin D1. Similar results were obtained with the NSCLC cell line NCI-H226, suggesting a role of this pathway in the down stream signaling mechanism produced by the zinc-dependent induction of KLF4. We also examined the potential anti-angiogenic activity of LOR-253, based on the results of our studies that demonstrated the down-regulation of the metal transcription factor 1 (MTF-1) gene expression in cancer cells treated with LOR-253. MTF-1 is an intracellular zinc sensor that regulates the transcription of zinc-sensitive genes involved in zinc homeostasis. It has been reported that MTF-1 regulates hypoxia-inducible factor-1\#945; (HIF-1\#945;), which plays important roles in angiogenesis pathways by regulating matrix metalloproteinases (MMPs). In addition, LOR-253 has been shown to induce KLF2 expression, which may alter the expression of vascular endothelial growth factor receptor (VEGFR) in endothelial cells. We found that LOR-253 was able to inhibit HUVEC cell mitogenesis and capillary formation in vitro. Immunohistochemical analyses of tumors isolated from LOR-253 treated mice showed reduced microvessel density, indicating inhibition of tumor angiogenesis. LOR-253 mediated down-regulation of MTF-1, HIF-1\#945;, and MMP2 was observed 24 hr after drug treatment in an H226 xenograft mouse model. Furthermore, up-regulated KLF2 and reduced VEGFR2 expression was demonstrated 24 hr after LOR-253 treatment in HUVEC cells. Taken together, the data support the potential anti-angiogenic activity of LOR-253.  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 1822.
A systematic review of person-centered approaches to investigating patterns of trauma exposure
Authors: Meaghan L. O'Donnell, Ingo Schaefer, Tracey Varker, Dzenana Kartal, David Forbes, Richard A.A. Bryant, Derrick Silove, Mark Creamer, Alexander McFarlane, Gin Malhi, Kim Felmingham, Miranda Van Hoof, Dusan Hadzi-Pavlovic, Angela Nickerson, Zachary Steel
Journal: Clinical Psychology Review (2017)
GP who deleted appointment slots to ease workload pressure is spared punishment
Authors: Clare Dyer
Journal: BMJ (2017)

A medical practitioners’ tribunal has taken the “exceptional course” of taking no action against the registration of a GP whose partners asked him to retire after learning that he had deleted some of his appointment slots to reduce his patient workload.

Andrew Thomson, who qualified in Dundee in 1996, made several admissions of dishonesty relating to the “coping mechanism” he employed to deal with his workload at the Academy Health Centre in Forfar, Scotland.

The tribunal held that Thomson’s fitness to practise was impaired but took no action after finding “powerful mitigating factors” in his case.

He deleted some of his appointment slots using the practice’s IT system and …
Transplantation of iPS-Derived Tumor Cells with a Homozygous MHC Haplotype Induces GRP94 Antibody Production in MHC-Matched Macaques
Authors: Hirohito Ishigaki, Toshinaga Maeda, Hirokazu Inoue, Tsuyoshi Akagi, Takako Sasamura, Hideaki Ishida, Toshiro Inubushi, Junko Okahara, Takashi Shiina, Misako Nakayama, Yasushi Itoh, Kazumasa Ogasawara
Journal: Cancer Research (2017)

Immune surveillance is a critical component of the antitumor response in vivo, yet the specific components of the immune system involved in this regulatory response remain unclear. In this study, we demonstrate that autoantibodies can mitigate tumor growth in vitro and in vivo We generated two cancer cell lines, embryonal carcinoma and glioblastoma cell lines, from monkey-induced pluripotent stem cells (iPSC) carrying a homozygous haplotype of major histocompatibility complex (MHC, Mafa in Macaca fascicularis). To establish a monkey cancer model, we transplanted these cells into monkeys carrying the matched Mafa haplotype in one of the chromosomes. Neither Mafa-homozygous cancer cell line grew in monkeys carrying the matched Mafa haplotype heterozygously. We detected in the plasma of these monkeys an IgG autoantibody against GRP94, a heat shock protein. Injection of the plasma prevented growth of the tumor cells in immunodeficient mice, whereas plasma IgG depleted of GRP94 IgG exhibited reduced killing activity against cancer cells in vitro These results indicate that humoral immunity, including autoantibodies against GRP94, plays a role in cancer immune surveillance. Cancer Res; 77(21); 6001-10. ©2017 AACR.
Incidence, Demographics, and Clinical Characteristics of Diabetes of the Exocrine Pancreas (Type 3c): A Retrospective Cohort Study
Authors: Chris Woodmansey, Andrew P. McGovern, Katherine A. McCullough, Martin B. Whyte, Neil M. Munro, Ana C. Correa, Piers A.C. Gatenby, Simon A. Jones, Simon de Lusignan
Journal: Diabetes Care (2017)

OBJECTIVE This study was conducted to describe the incidence of diabetes following pancreatic disease, assess how these patients are classified by clinicians, and compare clinical characteristics with type 1 and type 2 diabetes. RESEARCH DESIGN AND METHODS Primary care records in England (n = 2,360,631) were searched for incident cases of adult-onset diabetes between 1 January 2005 and 31 March 2016. We examined demographics, diabetes classification, glycemic control, and insulin use in those with and without pancreatic disease (subcategorized into acute pancreatitis or chronic pancreatic disease) before diabetes diagnosis. Regression analysis was used to control for baseline potential risk factors for poor glycemic control (HbA1c ≥7% [53 mmol/mol]) and insulin requirement. RESULTS We identified 31,789 new diagnoses of adult-onset diabetes. Diabetes following pancreatic disease (2.59 [95% CI 2.38–2.81] per 100,000 person-years) was more common than type 1 diabetes (1.64 [1.47–1.82]; P &amp;lt; 0.001). The 559 cases of diabetes following pancreatic disease were mostly classified by clinicians as type 2 diabetes (87.8%) and uncommonly as diabetes of the exocrine pancreas (2.7%). Diabetes following pancreatic disease was diagnosed at a median age of 59 years and BMI of 29.2 kg/m2. Diabetes following pancreatic disease was associated with poor glycemic control (adjusted odds ratio, 1.7 [1.3–2.2]; P &amp;lt; 0.001) compared with type 2 diabetes. Insulin use within 5 years was 4.1% (3.8–4.4) with type 2 diabetes, 20.9% (14.6–28.9) with diabetes following acute pancreatitis, and 45.8% (34.2–57.9) with diabetes following chronic pancreatic disease. CONCLUSIONS Diabetes of the exocrine pancreas is frequently labeled type 2 diabetes but has worse glycemic control and a markedly greater requirement for insulin.
Vincent van Gogh, <i>Madame Roulin With Baby</i>
Authors: M. Therese Southgate
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
connecting flight to Rochester, MN
Authors: D.A. Frater
Journal: Annals of Internal Medicine (2017)

Ad Libitum5 September 2017connecting flight to Rochester, MND.A. Frater, MDD.A. Frater, MDFrom Dallas, Texas.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M17-0425 Audio Reading - “connecting flight to Rochester, MN” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "connecting flight to Rochester, MN," by D.A. Frater. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail outside is deathbright drifts of inviting cumulussheens of cirrus lightnothing that we need for lifeas this membrane contains ustransports us by machinationsingenious enough past where webelong beyond the high mountainlimits to an airless desert voidwhere outside would freeze uslike so many fish in the skyinside we are still quietmost of us aware of ourfrailty in other ways acceptingnourishments small offers ofcomfort libations we forgetas we revisit prognoses rubbingsmooth the dome of our minds beforeeasing briefly the mask acrossour face as we try to keep ourselvesfrom falling into the aisle tryto remember that we are not yet dying Author, Article, and Disclosure InformationAffiliations: From Dallas, Texas.Current Author Address: D.A. Frater, MD; e-mail, [email protected]md. PreviousarticleNextarticle Advertisement Audio Reading - “connecting flight to Rochester, MN” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "connecting flight to Rochester, MN," by D.A. Frater. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 5 September 2017Volume 167, Issue 5Page: 356KeywordsFrailty ePublished: 5 September 2017 Issue Published: 5 September 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Case 27-2017
Authors: Douglas E. Drachman, David M. Dudzinski, Matthew P. Moy, Carlos Fernandez-del Castillo, Jonathan H. Chen
Journal: New England Journal of Medicine (2017)

A previously healthy 32-year-old man presented with the sudden onset of postprandial chest pain, nausea, and diaphoresis. An electrocardiogram showed concave ST-segment elevations. A diagnosis was made.
Abstracts&lt;xref ref-type="fn" rid="FN1"&gt;1&lt;/xref&gt;&lt;subtitle&gt;Preneoplasia in Breast Cancer&lt;/subtitle&gt;
Authors: Michael J. Brennan, M.D.
Journal: JNCI Journal of the National Cancer Institute (1972)

Abstracts: Preneoplasia in Breast Cancer Get access Michael J. Brennan, M.D. Michael J. Brennan, M.D. Michigan Cancer Foundation, Detroit, Michigan 48201 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 48, Issue 4, April 1972, Page 1241, https://doi.org/10.1093/jnci/48.4.1241 Published: 01 April 1972